Efficacy of modified levamisole adjuvant on inactivated virus vaccine

Viral Immunology

Volumn 19, Issue 3, 2006, Pages 525-535

  Yin, Jiangmei ^a   Jin, Huali ^a   Kang, Youmin ^a   Xiao, Chong ^a   Zhao, Lin ^a   Li, Xiaolin ^a   Ding, Zheng ^a   Yang, Fu ^a   Zhu, Qinghong ^a   Wang, Bin ^a  

^a CHINA AGRICULTURAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; GLYCOPROTEIN P 15095; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; INACTIVATED VIRUS VACCINE; INTERFERON RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; LEVAMISOLE; MAJOR HISTOCOMPATIBILITY ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; OIL; POLOXAMER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; CELL MATURATION; CELLULAR IMMUNITY; CHICKEN; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; DRUG EFFICACY; DRUG FORMULATION; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGLOBULIN PRODUCTION; IMMUNOSTIMULATION; LETHAL DOSE; LYMPHOCYTE PROLIFERATION; MOUSE; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TH1 CELL; TH2 CELL; VIRUS VIRULENCE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CHICKENS; DENDRITIC CELLS; FEMALE; HYPERSENSITIVITY, DELAYED; LEVAMISOLE; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; NEWCASTLE DISEASE; NEWCASTLE DISEASE VIRUS; POULTRY DISEASES; T-LYMPHOCYTES, HELPER-INDUCER; VACCINATION; VACCINES, INACTIVATED; VIRAL VACCINES;

GALLUS GALLUS; NEWCASTLE DISEASE VIRUS;

EID: 33750951950     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2006.19.525     Document Type: Conference Paper

References (47)

1. O'Hagan DT, MacKichan ML, and Singh M: Recent developments in adjuvants for vaccines against infectious diseases. Biomol. Eng. 2001;18:69-85.
2. Gupta RK, Relyveld EH, Lidbald EB, Bizzini B, Ben-Efraim S, and Gupta CK: Adjuvants: A balance between toxicity and adjuvanticity. Vaccine 1993;11:293-306.
3. Barteling SJ and Vreeswijk J: Developments in foot-and-mouth disease vaccines. Vaccine 1991;9:75-88.
4. Hardegree MC and Pittman M: Influence of antigens on release of free fatty acids from Arlacel A (mannide monooleate). Proc. Soc. Exp. Biol. Med. 1967;123:179-182.
5. Zinkernagel RM, Ehl S, and Aichele P: Antigen localization regulates immune responses in a dose and time-dependent fashion: A geographical view of immune reactivity. Immunol. Rev. 1997;156:199-209.
6. Lindblad EB, Elhay MJ, Silva R, Appelberg R, and Andersen P: Adjuvant modulation of immune responses to tuberculosis subunit vaccines. Infect. Immun. 1997;65:623-629.
7. Zigterman GJ, Snippe H, Jansze M, and Willers JM: Adjuvant effects of nonionic block polymer surfactants on liposome-induced humoral immune response. J. Immunol. 1987;138:220-225.
8. Hunter RL: Overview of vaccine adjuvants: present and future. Vaccine 2002;20:S7-S12.
9. O'Hagan DT and Valiante NM: Recent advances in the discovery and delivery of vaccine adjuvants. Nat. Rev. 2003;2:727-735.
10. Takeda K, Kaisho T, and Akira S: Toll-like receptors. Annu. Rev. Immunol. 2003;21:335-376.
11. Laurie JA, Moertel CH, and Fleming TR: Surgical adjuvant therapy of large-bowel carcinoma: An evaluation of levamisole and the combination of levamisole and fluorouracil. J. Clin. Oncol. 1989;7:1447-1459.
12. Jin H, Li Y, Ma Z, Zhang F, Xie Q, Gu D, and Wang B: Effect of chemical adjuvants on DNA vaccination. Vaccine 2004;22:2925-2935.
13. Johnkoski JA, Steven MP, Doerr JR, and Cohen AS: Levamisole regulates the proliferation of murine liver T cells through Kupffer-cell-derived cytokines. Cancer Immunol. Immunother. 1996;43:299-306.
14. Gould AR, Kattenbelt JA, Selleck P, Hansson E, Della-Porta A, and Westbury HA: Virulent Newcastle disease in Australia: Molecular epidemiological analysis of viruses isolated prior to and during the outbreaks of 1998-2000. Virus Res. 2001;77:51-60.
15. Liang R, Cao DJ, Li JQ, Chen J, Guo X, Zhuang FF, and Duan MX: Newcastle disease outbreaks in western China were caused by the genotypes VIIa and VIII. Vet. Microbiol. 2002;87:193-203.
16. Gallili GE, and Ben-Nathan D: Newcastle disease vaccines. Biotechnol. Adv. 1998;16:343-366.
17. Barteling SJ, and Vreeswijk J: Developments in foot-and-mouth disease vaccines. Vaccine 1991;9:75-88.
18. Davenport FM: Seventeen years' experience with mineral oil adjuvant influenza virus vaccines. Ann. Allergy 1968;26:288-292.
19. Roy P, Nachimuthu K, Koteeswaran A, Albert A, and Venugopalan AT: Postvaccinal immune response to regimens of Newcastle disease vaccination by filter paper sampling technique. Trop. Anim. Health Prod. 1997;29:20-24.
20. Reiner SL, Zheng S, Corry DB, and Locksley RM: Constructing polycompetitor cDNAs for quantitative PCR. J. Immunol. Methods 1993;165:37-46.
21. Kang Y, Jin H, Zheng G, Xie Q, Yin J, Yu Y, Xiao C, Zhang X, Chen A, and Wang B: The adjuvant effect of levamisole on killed viral vaccines. Vaccine 2005;23:5543-5550.
22. Lillehoj HS: Immune response during coccidiosis in SC and FP chickens. I. In vitro assessment of T cell proliferation response to stage-specific parasite antigens. Vet. Immunol. Immunopathol. 1986;13:321-330.
23. Mosmann T: Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983;65:55-63.
24. Koroliuk AM, Somov GP, and Sharapova TA: [Use of the indirect hemagglutination inhibition test in the study of and diagnosis of pseudotuberculosis (far eastern scarlatina-like fever)]. Zh. Mikrobiol. Epidemiol. Immunobiol. 1970;47:106-110.
25. Yamada K, Takasaki T, Nawa M, Yabe S, and Kurane I: Antibody responses determined for Japanese dengue fever patients by neutralization and hemagglutination inhibition assays demonstrate cross-reactivity between dengue and Japanese encephalitis viruses. Clin. Diagn. Lab. Immunol. 2003;10:725-728.
26. Letellier C, Burny A, and Meulemans G: Construction of a pigeonpox virus recombinant: Expression of the Newcastle disease virus (NDV) fusion glycoprotein and protection of chickens against NDV challenge. Arch. Virol. 1991;118:43-56.
27. Sakaguchi M, Nakamura H, Sonoda K, Okamura H, Yokogawa K, Matsuo K, and Hira K: Protection of chickens with or without maternal antibodies against both Marek's and Newcastle diseases by one-time vaccination with recombinant vaccine of Marek's disease virus type 1. Vaccine 1998;16:472-479.
28. Belardelli F: Role of interferons and other cytokines in the regulation of the immune response. APMIS 1995;103:161-179.
29. Heydtmann M, Shields P, McCaughan G, and Adams D: Cytokines and chemokines in the immune response to hepatitis C infection. Curr. Opin. Infect. Dis. 2001;14:279-287.
30. Kang J, and Der SD: Cytokine functions in the formative stages of a lymphocyte's life. Curr. Opin. Immunol. 2004;16:180-190.
31. Eckels DD: MHC: Function and implication on vaccine development. Vox Sang. 2000;78(Suppl. 2):265-267.
32. Clatza A, Bonifaz LC, Vignali DAA, and Moreno J: CD40-induced aggregation of MHC class II and CD80 on the cell surface leads to an early enhancement in antigen presentation. J. Immunol. 2003;171:6478-6487.
33. Thomsen AR, and Marker O: MHC and non-MHC genes regulate elimination of lymphocytic choriomeningitis virus and antiviral cytotoxic T lymphocyte and delayed-type hypersensitivity mediating T lymphocyte activity in parallel. J. Immunol. 1989;142:1333-1341.
34. + T cell infiltration, enables murine skin tumours to progress. Cancer Immunol. Immunother. 2003;52:396-402.
35. Tan P, Anasetti C, Hansen JA, Melrose J, Brunvand M, Bradshaw J, Ledbetter JA, and Linsley PS: Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J. Exp. Med. 1993;177:165-173.
36. Hon H, and Jacob J: Tracking dendritic cells in vivo: Insights into DC biology and function. Immunol. Res. 2004;29:69-80.
37. Fukanoki S, Matsumoto K, Mori H, and Takeda R: Relationship between antigen release and antibody response of infectious coryza water-in-oil-in-water emulsion vaccines. Avian Dis. 2000;44:869-873.
38. Singh M, and O'Hagan DT: Recent advances in veterinary vaccine adjuvants. Int. J. Parasitol. 2003;33:469-478.
39. Audibert F: Adjuvants for vaccines: A quest. Int. Immunopharmacol. 2003;3:1187-1193.
40. Kubo M, Hanada T, and Yoshimura A: Suppressors of cytokine signaling and immunity. Nat. Immunol. 2003;4:1169-1176.
41. Groux H, and Cottrez F: The complex role of interleukin-10 in autoimmunity. J. Autoimmun. 2003;20:281-285.
42. + T regulatory cells and is dependent on host-derived IL-10. J. Immunol. 2006;176:2635-2644.
43. Schjetne KW, Thompson KM, Aarvak T, Fleckenstein B, Sollid LM, and Bogen B: A mouse CK-specific T cell clone indicates that DC-SIGN is an efficient target for antibody-mediated delivery of T cell epitopes for MHC class II presentation. Int. Immunol. 2002;14:1423-1430.
44. Laurie JA, Moertel CG, Fleming TR, Wieand HS, Leigh JE, Rubin J, McCormack GW, Gerstner JB, Krook JE, and Malliard J: Surgical adjuvant therapy of large-bowel carcinoma: An evaluation of levamisole and the combination of levamisole and fluorouracil. North Central Cancer Treatment Group and the Mayo Clinic. J. Clin. Oncol. 1989;7:1447-1456.
45. Williams RA, Koroma MM, and Hodges M: Comparison of albendazole and levamisole chemotherapy on prevalence and intensity of common soil-transmitted helminth infections in school children, Sierra Leone. West Afr. J. Med. 1997;16:179-183.
46. Duclos P: A global perspective on vaccine safety. Vaccine 2004;22:2059-2063.
47. Jacobson RM: Vaccine safety. Immunol. Allergy Clin. North Am. 2003;23:589-603.